The Chemours Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CC research report →
Range $14 – $22
Price Chart
About the company
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment provides refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents under the Freon and Opteon brand names.
- CEO
- Denise Dignam
- IPO
- 2015
- Employees
- 5,700
- HQ
- Wilmington, DE, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a deep recovery regime after a long drawdown, trading well below its 200-day average of 18.28 and far under the 52-week high near 28.40. The setup is still damaged, but the price has stabilized above the 52-week low around 10.29, suggesting a base-building phase rather than a fresh breakdown.
Street sentiment is cautious: the consensus is Hold, with 7 Buy, 12 Hold, and 1 Sell ratings. The average target sits at 17.5, above the recent trading range but below prior cuts, and the last several calls skewed lower, including downgrades from RBC and UBS plus target reductions from Truist, Goldman Sachs, Barclays, and UBS.
The earnings profile is uneven, with 2 beats in the last 8 quarters and three straight misses in the most recent reports. Next-year EPS is expected to rebound to 1.7233 from 0.82681 in 2026, so shareholders should watch whether margin repair and volume stability can turn that forecast into a cleaner run rate.
Recent insider activity leans constructive, with 7 buys and no sells. Most of the signal came from discretionary purchases by the CEO, CFO, directors, and other officers, while award and in-kind transactions add noise but do not change the net buying pattern.
Profitability is still mixed, but cash generation is a bright spot. Gross margin is 15.3%, operating margin is 2.88%, and free cash flow reached 477 million in fiscal 2025, equal to 3.17 per share and a 23.85% yield. Leverage remains heavy with 4.585 billion of debt against 672 million of cash.
Chemours competes as a specialty chemicals name with exposure to refrigerants, titanium dioxide, and advanced materials, but its margin profile trails stronger peers. At about 18.46 times earnings, the valuation is not cheap for a company still working through low margins and elevated leverage.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.64B
- P/E
- -9.80
- Fwd P/E
- 13.31
- PEG
- -0.22
- P/S
- 0.28
- P/B
- 10.62
- EV/EBITDA
- 827.44
- Div Yield
- 3.22%
- Gross Margin
- 15.15%
- Op Margin
- -3.06%
- Net Margin
- -2.88%
- ROE
- -117.69%
- ROIC
- 10.06%
Latest fiscal year · YoY change
- Revenue
- $5.81B+0.4%
- Gross Profit
- $902.00M-21.6%
- Op Income
- $-5,000,000
- Net Income
- $-386,000,000-548.8%
- EPS
- $-2.57-543.1%
- OCF Growth
- +141.7%
- FCF Growth
- +105.1%
- 52W High
- $28.67
- 52W Low
- $10.51
- 50D MA
- $13.51
- 200D MA
- $18.20
- Beta
- 1.46
- RSI (14)
- 27
- Avg Volume
- 2.11M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Chemours posted a stronger-than-guidance quarter led by pricing and mix in TT and growth in APM, while TSS softened seasonally and the company raised full-year EBITDA and cash flow expectations despite higher settlement-related outflows.· November 3, 2026
- Net sales rose 3% year over year, with adjusted EBITDA at $200 million, the high end of guidance.
- TT benefited from 10% year-over-year global pricing and better execution despite weak end markets; APM also improved on higher-value mix and Performance Solutions growth.
- TSS faced expected seasonal softness in North American stationary AC aftermarket demand, with lower Opteon blend volumes and higher input costs, mainly sulfur.
- Management lifted full-year 2026 adjusted EBITDA guidance to $775 million-$800 million and expects net sales to grow around 2% versus 2025.
- Free cash flow conversion was lowered to 15%-20% due to settlement payments, restricted cash tied to the PFAS MOU, and working-capital timing; leverage is expected below 4.2x at year-end.
Chemours said third-quarter net sales were up 3% year over year and adjusted EBITDA was $200 million, at the high end of its guidance range. Denise Dignam said TT, TSS, and APM all contributed above expectations, while TT also had about $5 million of earnings benefit from sales and cost timing between Q3 and Q4. For Q4, management expects TSS adjusted EBITDA of $105 million-$115 million, TT adjusted EBITDA of $60 million-$65 million, and APM adjusted EBITDA of $40 million-$45 million. On a consolidated basis, Chemours now expects 2026 net sales to grow around 2% versus 2025 and adjusted EBITDA to be $775 million-$800 million. Free cash flow conversion is now expected to be 15%-20%, with capital expenditures of $220 million-$230 million, and net leverage is expected to be below 4.2x adjusted EBITDA at the end of 2026.
Denise Dignam framed the quarter as evidence that Chemours is executing well through weak macro conditions, with pricing discipline in TT, improving mix in APM, and long-term confidence in TSS. She emphasized the Pathway to Thrive strategy, highlighting balance-sheet de-risking through the North Carolina settlement, final New Jersey consent order approval, and the Kuan Yin land sale. Her tone was confident and forward-looking, especially around AI infrastructure, semiconductors, and liquid cooling as growth areas.
Shane W. Hostetter focused on the updated outlook and cash flow dynamics. He said the company now expects full-year adjusted EBITDA of $775 million-$800 million, free cash flow conversion of 15%-20%, and capex of $220 million-$230 million, with leverage below 4.2x. He attributed the lower cash flow outlook to restricted cash tied to the PFAS MOU, settlement payments for New Jersey and North Carolina, timing of working capital spend, and about $25 million of transaction taxes associated with Kuan Yin proceeds. He also noted debt reduction of €280 million for the year after a €50 million prepayment in Q3.
Analysts pressed on TSS input costs, with management saying the main increase was sulfur rather than R-32, and that they do not expect further changes in those raw material inputs. Several questions focused on whether TSS softness was more seasonality or channel destocking; management said the Q3-to-Q4 earnings drop is mostly normal seasonality and that clearer aftermarket visibility should return in late Q1 2027. Analysts also asked whether APM’s Q4 strength implies a higher normalized run rate; Shane said the business still looks like a $30 million-$40 million quarterly EBITDA business going into next year, despite Q4 being stronger. In TiO2, management said U.S. imports remain modest, that it will aggressively defend fair trade, and that it believes India’s antidumping protection should be durable.
The call showed clear execution in a tough environment: TT delivered 10% pricing gains, APM grew on higher-value Performance Solutions, and consolidated EBITDA came in at the high end of guidance. Management also sounded increasingly optimistic about AI infrastructure, data centers, semiconductors, and liquid cooling as longer-term growth vectors. Balance-sheet repair and litigation resolution also appeared to be progressing, which supports financial flexibility.
TSS is still facing seasonal weakness and softer North American stationary AC aftermarket demand, with management saying Q4 will remain weak before visibility improves later in Q1. Free cash flow guidance came down because of settlement payments, restricted cash, and working-capital timing, showing that legacy liabilities still pressure near-term cash generation. TT remains exposed to weak housing and broader macro conditions, and management acknowledged continued demand weakness in key regions even as pricing holds.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.0%
- Shares Outstanding
- 150.52M
- Float Shares
- 149.09M
of shares held by institutions
500 13F filers
Buy/sell ratio 1.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CC, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 22.52M | ▼ 763.95K |
| Vanguard Group Inc | 17.92M | ▲ 490.78K |
| Vanguard Portfolio Management LLC | 10.92M | ▲ 346.69K |
| Vanguard Capital Management LLC | 6.79M | ▲ 8.42K |
| State Street Corp | 6.08M | ▼ 32.33K |
| Jpmorgan Chase & Co | 5.76M | ▲ 1.56M |
| Ameriprise Financial Inc | 4.92M | ▲ 86.20K |
| Geode Capital Management, LLC | 3.78M | ▼ 47.41K |
| Cooper Creek Partners Management LLC | 3.70M | ▲ 1.98M |
| D. E. Shaw & Co., Inc. | 2.87M | ▲ 19.03K |
| Jefferies Financial Group Inc. | 2.74M | ▲ 1.96M |
| Highland Peak Capital, LLC | 2.64M | ▲ 1.18M |
Held by 370 ETFs
Biggest fund positions in CC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | MATHER COURTNEY | other | 2,118 |
| Aug 12, 26 | Will David | other | 2,426 |
| Aug 12, 26 | Familiar Calderon Gerardo | buy | 1,935 |
| Aug 11, 26 | Dignam Denise | buy | 3,378 |
| Aug 7, 26 | Cowan Alister | buy | 13,000 |
| Aug 7, 26 | Foley Michael Robert | buy | 1,934.231 |
| Aug 7, 26 | CRANSTON MARY B | buy | 6,000 |
| Aug 7, 26 | Martinko Joseph T. | buy | 1,939.801 |
| Aug 6, 26 | HOSTETTER SHANE | buy | 3,350 |
| Aug 6, 26 | HOSTETTER SHANE | other | 3,087 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CC coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Chemours Company (NYSE: CC) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
globenewswire.com · Nov 20
Bragar Eagel & Squire, P.C. Urges The Chemours Company Investors to Contact the Firm Before December 7th Seeking Lead Plaintiff Role
globenewswire.com · Nov 20
CC Investors: BFA Law Notifies Chemours Investors with Losses of the Filed Securities Fraud Class Action and Upcoming December 7 Court Deadline
globenewswire.com · Nov 20
Kaplan Fox Alerts The Chemours Company (CC) Investors to an Approaching Lead Plaintiff Deadline on December 7, 2026
newsfilecorp.com · Nov 20
CC Investors Have Opportunity to Lead The Chemours Company Securities Fraud Lawsuit with SBS Law
prnewswire.com · Nov 19
The Chemours Company Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CC
prnewswire.com · Nov 19
Faruqi & Faruqi, LLP Urges The Chemours (CC) Investors to Seek Counsel Before the December 7, 2026 Lead Plaintiff Deadline in the Securities Class Action
newsfilecorp.com · Nov 19
CC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in The Chemours Company Securities Lawsuit - Contact SueWallSt
prnewswire.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice
